What The 2024 NCCN Guidelines Say About... It does if a single state in the U.S. is any indication. In North Carolina, significantly higher rates of prostate cancer recurrence were reported among men ...

Researchers in Denmark conducted a prospective single-centre study including 160 patients with newly diagnosed high-risk prostate cancer between 2021 and 2024. All the participants first underwent an ...

LOS ANGELES (KABC) -- New technology that's allowing doctors to pinpoint prostate cancer long before it becomes a threat is now widely available. A former firefighter mentioned how this new imaging ...

Prostate-specific membrane antigen (PSMA)-PET/CT imaging identified metastatic prostate cancer in almost half of high-risk cases missed by conventional imaging, a retrospective analysis showed.

PSMA-PET has an important role in the accurate staging of recurrent prostate cancer. Prostate-specific membrane antigen-positron emission tomography (PSMA-PET) frequently detects metastatic disease ...

To advance the clinical adoption of precision medicine, the symposium “Advances in Precision Diagnosis for Suspected Prostate Cancer: A Comprehensive Symposium on PSMA PET Imaging and Biomarkers” was ...

Surgery patients staged with PSMA-PET appear to have a lower risk of early BCR than those staged with conventional imaging. Early oncologic outcomes after radical prostatectomy (RP) for very high risk ...

@2024 - All Right Reserved.

A new radioactive diagnostic agent for use in prostate cancer has been approved by the US Food and Drug Administration (FDA). The product, Gallium 68 PSMA-11 (Ga 68 PSMA-11), has been approved for ...

Dr. Glenn Bauman, Scientist at LHSCRI and Radiation Oncologist at London Health Sciences Centre (LHSC), stands in front of the positron emission tomography (PET) scanner. LONDON, ON – A multicentre ...

Liv Hospital integrates PET/CT diagnostics, radionuclide therapies and a multidisciplinary council to create individualized treatment plans for complex cancer and cardiac cases.